News
- All
- Cardiovascular
- Central Nervous System
- Gastroenterology
- Respiratory
- Syncrosome News
Syncrosome: what did we change in 2016?
The end of 2016 is near, and with the closure of this year comes the joy of Christmas, holidays and celebrations, but before we head off to spend time with our families, we would like to thank you for your devotion throughout 2016. Let’s remember...
23 décembre, 2016
Mouse ischemia reperfusion: a good preclinical model for myocardial infarction?
Myocardial infarction (MI) results from a biphasic ischemia/reperfusion (I/R) injury to the heart. The disease is linked to cardiomyocyte apoptosis and further along to inflammation-based tissue damage. Despite considerable effort, therapeutic interventions to disrupt this injury pattern are not optimal. Indeed, the inflammation's multifactorial nature complicates...
12 décembre, 2016
SYNCROSOME CIR accreditation
For more than 6 years now, Syncrosome has worked as a preclinical CRO accredited by the French Ministry of Higher Education and Research for Research Tax Credits (CIR). Our recognition procures a significant financial benefit for French companies wishing to pursue their R & D work in Cardiovascular, Central...
09 décembre, 2016
Organ cross talk in DSS induced colitis can be effectively treated with anti-inflammatory molecule
Inflammatory bowel disease (IBD), consisting of Crohn’s disease (CD) and ulcerative colitis (UC), involves chronic inflammation of all or part of the digestive tract and millions are affected around the world. Researchers currently believe that an unregulated immune response to resident intestinal bacteria, influenced by...
01 décembre, 2016
Syncrosome sets up a new preclinical PAH (Pulmonary Arterial Hypertension) model in mouse.
Pulmonary arterial hypertension (PAH) is a syndrome in which pulmonary arterial obstruction increases pulmonary vascular resistance, leading to right ventricular hypertrophy (RVH), failure, and death. The development of small-animal preclinical models of PAH is a necessary challenge in order to test the efficacy of new...
23 novembre, 2016
Syncrosome keeps increasing its In vivo Preclinical skills
In the framework of our development, we are proud to announce the recruitment of our new scientific colleague, Guénaelle CANET. She will work in our Technical Department at the Lab and will be in charge, with the scientific and technical team, of setting up different...
15 novembre, 2016
Parkinson 6 OHDA preclinical: New POC on rat to repair neurons, with new compound.
Researchers from the college of Pharmaceutical Sciences in China have recently studied a compound that enhances neuronal recovery in a rat model of Parkinson’s disease (Parkinson 6 OHDA). Parkinson’s disease is a chronic disorder of the central nervous system, caused primarily by the progressive loss...
11 novembre, 2016
Evaluating preclinical emesis induced by PDE4 inhibitors via a noradrenergic pathway
Emesis and/or Nausea are commonly reported side effects associated with several drugs such as 4 phosphodiesterase (PDE4) inhibitors and is a major drawback for the therapeutic use of these drugs. The mechanism responsible for this side effect has been investigated in an attempt to discover...
07 novembre, 2016
Join Syncrosome team at Bio-Europe in Cologne, Germany, next week!
Syncrosome invites you to visit us at Bio-Europe, November 7th to November 9th 2016, in Cologne, Germany. Emmanuelle Bettendorf, our Business Developer would be delighted to meet you their and discuss your in vivo preclinical projects. We can give you advice about our in vivo efficacy, CNS-PK...
03 novembre, 2016